In addition, CQ/HCQ treatment also prevented IκBα degradation, consistent with a previous report showing that the inhibition of autophagy by CQ blocks bortezomib-induced NF-κB activation in diffuse large B-cell lymphoma (DLBCL) cells [31]. Here, NFKBIA is linked to diffuse large B-cell lymphoma.